| abstract |
Disclosed is the use of ulipristal acetate, or any metabolite thereof selected from the group comprising CDB-3877, CDB-3963, CDB-3236, and CDB-4183, in the manufacture of a medicine for normalizing menstrual bleeding on the long-term in a subject suffering from uterine fibroids and/or adenomyosis, wherein the treatment related to normalizing menstrual bleeding comprises administering, before undergoing a vascular occlusion method or a thermal related treatment method, a dosage of ulipristal acetate, or any metabolite thereof. |